Showing 381-390 of 2936 results for "".
- Galderma Gives Back: New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://modernaesthetics.com/news/galderma-gives-back-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2473049/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Managing Employees During the COVID Pandemic: Answers to Top Questionshttps://modernaesthetics.com/news/managing-employees-in-the-covid-pandemic-answers-to-top-questions/2473040/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential e
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- ZO Skin Health Adds Colleen Goggins to Board of Directorshttps://modernaesthetics.com/news/zo-skin-health-adds-colleen-goggins-to-board-of-directors/2473024/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu